Skip to content
value.today
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

ALGS
$43 Mmarket cap on Aug 1, 2026-23.2% since Jan 2024
Compare
World rank
#21,783
Revenue
$2 M
For year ending December-2025
Net income
$-24 M
-1104.6% margin
SEC filing
Employees
67
As on June-2020
value.today research

Aligos Therapeutics, Inc. in brief

Aligos Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $43 M on 1 August 2026, which makes it the 21,783rd largest listed company in the world and the 3,921st largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $24 M. It employs about 67 people and Lawrence Blatt is its chief executive. Its shares trade under the symbol ALGS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Aligos Therapeutics, Inc.

Aligos Therapeutics is a Clinical Stage Biopharmaceutical company leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage expertise in liver diseases. The company total assets is 146.5 million USD and total equity is 64.9 million USD as on 2019. The headquarters is in USA.

Aligos Therapeutics, Inc. timeline

2 events, 2020
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 19 October 2020; shares registered for exchange trading on 13 October 2020.

Events of Aligos Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$285 M$569 M$854 M$1.1 B202120222023202420252026

World rank over time

▼ down 12,125 places since 2021
2021-01-01: #7730#7,73020212022-01-07: #19791#19,79120222022-12-25: #26345#26,34520222023-07-30: #26584#26,58420232024-01-05: #24404#24,40420242026-03-08: #11138#11,13820262026-08-01: #19855#19,8552026

Rank in USA: #2,191 (Jan 2021) · #4,002 (Jan 2022) · #4,951 (Dec 2022) · #4,895 (Jul 2023) · #4,005 (Jan 2024) · #2,167 (Mar 2026) · #3,780 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
19.6×
Price / book
0.8×
Free cash flow yield
-188.1%
Net margin
-1104.6%
Operating margin
-4017.4%
Return on equity
-45.2%
Liabilities / assets
39.5%
Revenue growth
-39.3%
R&D / revenue
3171.2%
Revenue per employee
$33 K
Profit per employee
$-361 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-52M—FY19Fiscal year ending Dec 2020: revenue —, net income $-109M—FY20Fiscal year ending Dec 2021: revenue —, net income $-128M—FY21Fiscal year ending Dec 2022: revenue —, net income $-96M—FY22Fiscal year ending Dec 2023: revenue $6M, net income $-88M$6MFY23Fiscal year ending Dec 2024: revenue $4M, net income $-131M$4MFY24Fiscal year ending Dec 2025: revenue $2M, net income $-24M$2MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$2M-39.3%$-88M$-24M-1104.6%
Dec 2024$4M-41.7%$-89M$-131M-3634.6%
Dec 2023$6M—$-88M$-88M-1416.5%
Dec 2022——$-98M$-96M—
Dec 2021——$-128M$-128M—
Dec 2020——$-98M$-109M—
Dec 2019——$-54M$-52M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-83M——$-2.45—
Dec 2024$-81M$0M$-81M$-20.94—
Dec 2023$-79M$0M$-79M$-34.20—
Dec 2022$-79M$1M$-80M$-2.25—
Dec 2021$-116M$1M$-117M$-3.22—
Dec 2020$-74M$2M$-76M$-10.87—
Dec 2019$-47M$3M$-50M$-26.04—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-82M$1MDec ’24Three months to Mar 2025: revenue $0M, net income $43M$0MMar ’25Three months to Jun 2025: revenue $1M, net income $-16M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-32M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-20M$0MDec ’25Three months to Mar 2026: revenue $3M, net income $-23M$3MMar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue $3M, net income $-22M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M (+282.4% on a year earlier), net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Aligos Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-88 M
Net income
$-24 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$89 M
Total liabilities
$35 M
Total equity
$54 M

As of December-2025

Top 36 institutional investors in Aligos Therapeutics, Inc.#

As of Sep 30, 2026
36 institutions held 2.5 M shares (about 24.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 20.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Aligos Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Deep Track Capital, LP444,1100 (0.00%)4.37%$3 MNov 16, 2026
2Sio Capital Management, LLC327,2370 (0.00%)3.22%$2 MNov 16, 2026
3Parkman Healthcare Partners LLC325,537New3.20%$2 MNov 16, 2026
4Marshall Wace, LLP246,5790 (0.00%)2.43%$1 MNov 13, 2026
5Schonfeld Strategic Advisors LLC181,880New1.79%$1 MNov 16, 2026
6Woodline Partners LP177,3620 (0.00%)1.74%$1 MNov 16, 2026
7Vanguard Capital Management LLC175,5430 (0.00%)1.73%$1 MNov 13, 2026
8Baker Bros. Advisors LP83,0550 (0.00%)0.82%$0 MNov 16, 2026
9Hhlr Advisors, LTD.76,2470 (0.00%)0.75%$0 MNov 16, 2026
10D. E. Shaw & Co., Inc.71,528+5,065 (+7.62%)0.70%$0 MNov 16, 2026
11UBS Group AG67,298+7,312 (+12.19%)0.66%$0 MNov 10, 2026
12Geode Capital Management, LLC50,310+3,137 (+6.65%)0.49%$0 MNov 6, 2026
13Prudential Financial Inc45,354New0.45%$0 MNov 16, 2026
14LPL Financial LLC38,170New0.38%$0 MNov 6, 2026
15BlackRock, Inc.29,536-756 (-2.50%)0.29%$0 MNov 13, 2026
16Vanguard Fiduciary Trust Co28,6120 (0.00%)0.28%$0 MNov 13, 2026
17Two Sigma Investments, LP27,522New0.27%$0 MNov 16, 2026
18Dimensional Fund Advisors LP21,0440 (0.00%)0.21%$0 MNov 4, 2026
19Gsa Capital Partners LLP20,714New0.20%$0 MNov 16, 2026
20Trexquant Investment LP19,395+7,056 (+57.18%)0.19%$0 MNov 16, 2026
21Verition Fund Management LLC18,8870 (0.00%)0.19%$0 MNov 13, 2026
22Renaissance Technologies LLC15,100+4,300 (+39.81%)0.15%$0 MNov 12, 2026
23Quadrature Capital Ltd13,406New0.13%$0 MNov 13, 2026
24Citadel Advisors LLC11,539New0.11%$0 MNov 16, 2026
25Rockefeller Capital Management L.P.10,276+276 (+2.76%)0.10%$0 MNov 13, 2026
Show all 36: investors 26 to 36
Institutional investors 26 to 36 in Aligos Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Federation des caisses Desjardins du Quebec3,300-1,350 (-29.03%)0.03%$0 MNov 16, 2026
27Golden State Wealth Management, LLC2,6740 (0.00%)0.03%$0 MNov 2, 2026
28Royal Bank Of Canada2,231+106 (+4.99%)0.02%$0 MNov 16, 2026
29Morgan Stanley205+1 (+0.49%)0.00%$0 MNov 13, 2026
30Osaic Holdings, Inc.200New0.00%$0 MNov 12, 2026
31Jpmorgan Chase & Co26-318 (-92.44%)0.00%$0 MNov 12, 2026
32SBI Securities Co., Ltd.26-100 (-79.37%)0.00%$0 MOct 22, 2026
33Tower Research Capital LLC (TRC)5-354 (-98.61%)0.00%$0 MNov 16, 2026
34Elevation Wealth Partners, LLC40 (0.00%)0.00%$0 MOct 7, 2026
35BNP Paribas Financial Markets30 (0.00%)0.00%$0 MNov 12, 2026
36Barclays PLC1New0.00%$0 MNov 6, 2026

Mutual funds holding Aligos Therapeutics, Inc.#

18 funds hold shares worth $1 M (about 2.6% of the company). Since their previous reports 12 added shares and 4 sold, buying $0 M net.
Mutual funds holding Aligos Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.128,770$1 M1.3%<0.01%+1.4%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.46,773$0 M0.46%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC24,809$0 M0.24%<0.01%−7.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors16,428$0 M0.16%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,553$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP8,329$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC6,141$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,569$0 M0.04%<0.01%+90%May 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC3,200$0 M0.03%<0.01%+321%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP3,573$0 M0.04%<0.01%+6.8%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP2,810$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP2,093$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust1,427$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP1,855$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,090$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP1,149$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust332$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC178$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 18 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Aligos Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
11
since
Aligos Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Carole NuechterleinDirector, 10% ownerBuyindirect+7.93 M$0.760$6.0 M11.03 MForm 4
filed James Paul ScopaDirectorGrant or award+183,083$0.760$139 K183,083Form 4
filed Lawrence BlattChief Executive Officer, DirectorGrant or award+610,277$0.760$464 K1.85 MForm 4
filed Thomas WoiwodeDirectorOther10b5-1 plan · indirect-485,979——1.46 MForm 4
filed Thomas WoiwodeDirectorOtherindirect+9,719——9,719Form 4
filed Thomas WoiwodeDirectorOtherindirect-9,719——0Form 4
filed Thomas WoiwodeDirectorOtherindirect+8,383——8,383Form 4
filed Thomas WoiwodeDirectorOtherindirect-8,383——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Aligos Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
677,218
11.0% of shares · 20.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split ; 1-for-1.11 reverse split

Trading halts

  • 2024-11-19 19:32 UTC, code LUDP, resumed 19:37 UTC
  • 2024-11-19 19:22 UTC, code LUDP, resumed 19:32 UTC
  • 2024-11-19 19:11 UTC, code LUDP, resumed 19:21 UTC
  • 2024-11-19 18:59 UTC, code LUDP, resumed 19:04 UTC
  • 2024-11-19 18:52 UTC, code LUDP, resumed 18:57 UTC

Fails to deliver

  • : 1,384 shares at $4.74
  • : 92 shares at $4.82
  • : 819 shares at $4.96
  • : 1,249 shares at $5.03
  • : 216 shares at $4.84

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Aligos Therapeutics, Inc. scorecard#

Passes 2 of the 10 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 3
    • ✗Revenue grew in the newest year-39.3%Revenue down 39.3% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.45 vs -20.94Diluted EPS -2.45 in fiscal 2025 against -20.94 the year before (report's currency).
    • ✓Net income higher than five years earlier-$24 M-$24 M in fiscal 2025 against -$109 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-196.9%-196.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.90 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-11.84Z-score -11.84 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year57.8%Diluted shares up 57.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Aligos Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Aligos Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue2.23.66.2000—
Research and development697073851048044
General and administrative21233126291810
Operating expenses90931041111339854
Operating income−88−89−88−98−128−98−54
Net interest income2.21.74.31.5———
Income before tax−24−131−87−96−128−108−52
Income tax0.30.30.80.10.10.20.1
Net income attributable to shareholders−24−131−88−96−128−109−52
Earnings per share, basic-2.45-20.94-34.20r-2.25-3.22-10.87-26.04
Earnings per share, diluted-2.45-20.94-34.20r-2.25-3.22-10.87-26.04
Shares, weighted average (basic)9.96.32.6r43———
Shares, weighted average (diluted)9.96.32.6r434010.02.0
Balance sheet
Cash and cash equivalents18371368118722070
Short-term investments6020—443.92348
Other current assets4.95.15.37.6145.92.0
Current assets8362141134204250120
Property, plant and equipment1.92.43.34.86.28.08.5
Right-of-use (leased) assets3.15.06.67.78.86.97.6
Long-term investments————15—10
Total assets8970152147235265147
Accounts payable4.02.62.54.73.03.33.8
Current liabilities21222433393014
Lease liabilities (non-current)1.54.87.79.2111012
Total liabilities35995943514529
Retained earnings−642−618−487−399−303−175−66
Shareholders' equity54−2992104185220−65
Total liabilities and equity8970152147235265147
Shares outstanding6.23.93.0r434338r3.9
Cash-flow statement
Share-based compensation5.08.51315133.00.8
Cash from operating activities−83−81−79−79−116−74−47
Capital expenditure—−0.1−0.0−0.9−0.9−2.1−2.8
Cash from investing activities−38−1845−263.0336.8
Shares issued——0.0————
Cash from financing activities1020.4880.27919286
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Aligos Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 8 · Material agreement 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 3 · Results announced 11

Aligos Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Delisting noticeDirectors and officers8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Aligos Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$105 MPrivate placement after listing$50 to $250 million12equity, optionsSEC
Oct 2023$92 MPrivate placement after listing$50 to $250 million11equity, optionsSEC
Dec 2019$85 MNo. 1$50 to $250 million38equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Aligos Therapeutics, Inc.#

$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on labor issues/antitrust/workplace.

Lobbying, 2025
$80 K
#1,293 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$140 K
  • Labor Issues/Antitrust/Workplace1 report

Lobbying firms hired in 2025

Wilmer Cutler Pickering Hale and Dorr LLP $80 K

Aligos Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$140 K—3
2025$80 K—4
2024$0—4
2023$220 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Aligos Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Aligos Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $248 K a year.

Certified, FY2026
2
#1,565 among companies on value.today
Worker positions
2
Median wage offered
$248 K
a year, full-time
Applications filed
2
Aligos Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Director of Clinical OperationsNatural Sciences Managers2$248 K

Where: San Francisco, CA 1 · South San Francisco, CA 1

Aligos Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$248 K2
FY202411$230 K1
FY202311$131 K1
FY202211$131 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aligos Therapeutics, Inc.

How Aligos Therapeutics, Inc. compares in Biotechnology

  • Market cap$43 M · higher than 24% of 726
  • Revenue$2 M · higher than 31% of 647
  • Revenue growth-39.3% · higher than 24% of 438
  • Price / sales19.6× · lower than 32% of 339
  • Price / book0.8× · lower than 83% of 534
  • FCF yield-188.1% · higher than 1% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Aligos Therapeutics, Inc.🇺🇸$43 M——-39.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on June-2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Aligos Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Aligos Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Aligos Therapeutics, Inc.? Suggest a correction